John Boozman bought DexCom Inc (NASDAQ: DXCM)
John Boozman (R-AR), a U.S. Senator, has disclosed 1 trade in DexCom Inc (DXCM) since 2026, a single purchase, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a purchase: John Boozman bought $1,001 - $15,000 of DexCom Inc (NASDAQ: DXCM) on January 26, 2026. Since that trade, DXCM is up +2.45% against the S&P 500 up +5.59%, an outperformance of -3.14%.
Data updated
John Boozman's DXCM trades vs the price
DXCM is up +2.45% since John Boozman bought on January 26, 2026, versus +5.59% for the S&P 500.
Performance since this trade
All John Boozman DXCM trades
John Boozman & DXCM trading FAQ
Is it legal for John Boozman to trade DexCom Inc (DXCM) stock?
Yes. Members of Congress are allowed to trade individual stocks, including DexCom Inc (DXCM), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did John Boozman buy DXCM?
John Boozman disclosed a purchase of $1,001 - $15,000 of DexCom Inc (DXCM) on January 26, 2026, according to public STOCK Act filings.
How has DXCM performed since John Boozman's trade?
Since John Boozman bought DXCM on January 26, 2026, the stock is up +2.45%, versus +5.59% for the S&P 500 over the same period, an outperformance of -3.14%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional DXCM trades?
Quantellect tracks every disclosed congressional trade in DexCom Inc (DXCM) on the DexCom Inc congressional trading page, which aggregates filings across all members of Congress.
John Boozman's DXCM tradesAll congressional filings for DexCom IncJohn Boozman's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.